Graeme Young

1.0k citations

37 papers · 665 · h-index 15

Impact in

Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
Pharmaceutical Science top 10%

Papers in

Molecular Biology 12
Pediatrics, Perinatology and Child Health 7
- Pharmaceutical studies and practices 5

Co-authors: Claire Beaumont (4 shared papers)Malcolm A. Young (1 shared paper)Tom M. Cavalier (1 shared paper)Mark Seymour (3 shared papers)Tal Burt (2 shared papers)Yuichi Sugiyama (2 shared papers)P. V. Colthup (2 shared papers)Erika K. Hussey (1 shared paper)
Journals: Drug Metabolism and Disposition (7 papers)Bioanalysis (6 papers)British Journal of Clinical Pharmacology (3 papers)Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms (2 papers)Clinical Pharmacology & Therapeutics (2 papers)
Partner nations: United Kingdom United States Belgium

In The Last Decade

Graeme Young

37 papers receiving 625 citations

Peers

Countries citing papers authored by Graeme Young

Since Specialization

Citations

This map shows the geographic impact of Graeme Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graeme Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graeme Young more than expected).

Fields of papers citing papers by Graeme Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graeme Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graeme Young. The network helps show where Graeme Young may publish in the future.

Co-authors

The 25 scholars most cited alongside Graeme Young, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Graeme Young Line = papers co-authored together Graeme Young links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase 0/microdosing approaches: time for mainstream application in drug development? Nature Reviews Drug Discovery ·Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama	2020	56
2	A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts Journal of Pharmaceutical and Biomedical Analysis ·R. Colin Garner, James Barker, C Flavell, John Garner, M Whattam, Graeme Young, N. J. CUSSANS, S. G. Jezequel, David Tai Leong	2000	49
3	Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans Drug Metabolism and Disposition ·Andrew W. Harrell, Sarah Siederer, Jo Bal, Nainesh H. Patel, Graeme Young, Clive C. Felgate, Sebastian J. Pearce, Andy D. Roberts, Claire Beaumont, Amanda Emmons, Adrian Pereira, Rodger Kempsford	2012	46
4	Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches British Journal of Clinical Pharmacology ·Claire Beaumont, Graeme Young, Tom M. Cavalier, Malcolm A. Young	2014	45
5	Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique Xenobiotica ·Graeme Young, William Ellis, John Ayrton, Erika K. Hussey, B. Adamkiewicz	2001	44
6	Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study BMC Pharmacology and Toxicology ·Anthony Cahn, Simon T. Hodgson, Robert C. Wilson, Jonathan Robertson, Joanna Watson, Misba Beerahee, Steve C Hughes, Graeme Young, Rebecca H. Graves, David A. Hall, Sjoerd van Marle, Roberto Solari	2013	42
7	Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours British Journal of Clinical Pharmacology ·Cathrine Leonowens, Carolyn Pendry, John W. Bauman, Graeme Young, May Y. K. Ho, Frank Henriquez, (unknown), Royce A. Morrison, Keith Orford, Danièle Ouellet	2014	35
8	Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors The Journal of Clinical Pharmacology ·Cathrine L. Denton, Elisabeth A. Minthorn, Stanley W. Carson, Graeme Young, Lauren E. Richards‐Peterson, Jeffrey Botbyl, Chao Han, Royce A. Morrison, Samuel C. Blackman, Danièle Ouellet	2013	30
9	Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic Drug Metabolism and Disposition ·Gary D. Bowers, David M. Tenero, Parul Patel, Phuong Tu Huynh, James Sigafoos, Kathryn O’Mara, Graeme Young, Étienne Dumont, Elizabeth Cunningham, Milena Kurtinecz, Patrick Stump, J. J. Conde, John P. Chism, Melinda J. Reese, Yun Lan Yueh, John Tomayko	2013	23
10	Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper Clinical Pharmacology & Therapeutics ·Graeme Young, Douglas K. Spracklin, Alexander D. James, Mette G. Hvenegaard, Graeme Scarfe, David S. Wagner, Katrin Georgi, Hanno Schieferstein, Inga Bjørnsdottir, Bianca D. van Groen, Andrea A. Romeo, Kenneth C. Cassidy, Georges Da‐violante, Bojan Bister, Stefan Blech, Ramaswamy Lyer, Simone I. Schulz, Filip Cuyckens, Patricia Moliner	2022	23
11	Comparison of a 250 kV single‐stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer – fitness for purpose in bioanalysis Rapid Communications in Mass Spectrometry ·Graeme Young, S. Corless, Clive C. Felgate, P. V. Colthup	2008	23
12	European Bioanalysis Forum Recommendation: Scientific Validation of Quantification by Accelerator Mass Spectrometry Bioanalysis ·David Higton, Graeme Young, Philip Timmerman, Richard Abbott, Magnus Knutsson, Leif Svensson	2012	21
13	An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects Drug Metabolism and Disposition ·Andrew W. Harrell, Robert C. Wilson, Yau Lun Man, Kylie Riddell, Emily Jarvis, Graeme Young, R. Andrew Chambers, Lee Crossman, Alex Georgiou, Adrian Pereira, David Kenworthy, Claire Beaumont, Miriam Marotti, Denisa Wilkes, Edith M. Hessel, William A. Fahy	2019	18
14	A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study Antimicrobial Agents and Chemotherapy ·Étienne Dumont, Amanda J. Oliver, Christos V. Ioannou, Julia Billiard, Jeremy Dennison, Frans van den Berg, Shuying Yang, Vijayalakshmi Chandrasekaran, Graeme Young, Anirban Lahiry, David C. Starbuck, Andrew W. Harrell, Alex Georgiou, Nathalie Hopchet, Andy Gillies, Stephen J. Baker	2020	15
15	AMS Method Validation for Quantitation in Pharmacokinetic Studies with Concomitant Extravascular and Intravenous Administration Bioanalysis ·Graham Lappin, Mark Seymour, Graeme Young, David Higton, Howard Hill	2011	15
16	New Frontiers—Accelerator Mass Spectrometry (AMS): Recommendation for Best Practices and Harmonization from Global Bioanalysis Consortium Harmonization Team The AAPS Journal ·Graeme Young, Mark Seymour, Stephen R. Dueker, Philip Timmerman, Ali Arjomand, Kohei Nozawa	2014	14
17	AMS in drug development at GSK Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms ·Graeme Young, William J. Ellis	2007	14
18	Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development Alternatives to Laboratory Animals ·Tal Burt, Le T. Vuong, Elizabeth Baker, Graeme Young, A. Daniel McCartt, Mats Bergström, Yuichi Sugiyama, Robert D. Combes	2018	13
19	Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans Drug Metabolism and Disposition ·Mehul Dave, Mike Nash, Graeme Young, Harma Ellens, Mindy Magee, Andrew D. Roberts, Maxine Taylor, Robert W. Greenhill, Gary W. Boyle	2013	13
20	Best Practices for Metabolite Quantification in Drug Development: Updated Recommendation from The European Bioanalysis Forum Bioanalysis ·Philip Timmerman, Stefan Blech, Stephen White, Martha Green, Claude Delatour, Stuart McDougall, Geert Mannens, John Smeraglia, Stephen J. Williams, Graeme Young	2016	13

About Graeme Young

Graeme Young is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health, Physiology, Oncology and Immunology, having authored 37 papers that have together received 665 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (5 papers), Biosimilars and Bioanalytical Methods (5 papers), Asthma and respiratory diseases (5 papers), Pharmaceutical studies and practices (5 papers), Inhalation and Respiratory Drug Delivery (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Mass Spectrometry Techniques and Applications (4 papers) and Chemical Reactions and Isotopes (4 papers). The work is most often cited by research in Pharmacology (139 citations), Pharmaceutical Science (48 citations), Spectroscopy (96 citations), Immunology (92 citations) and Oncology (113 citations). Graeme Young has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Claire Beaumont, Malcolm A. Young, Tom M. Cavalier, Mark Seymour, Tal Burt, Yuichi Sugiyama, P. V. Colthup, Erika K. Hussey, William Ellis and Adrian Pereira. Their work appears in journals such as Drug Metabolism and Disposition, Bioanalysis, British Journal of Clinical Pharmacology, Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Graeme Young

Impact in

Papers in i

In The Last Decade

Graeme Young

Peers

Countries citing papers authored by Graeme Young

Fields of papers citing papers by Graeme Young

All Works

About Graeme Young

Explore authors with similar magnitude of impact

Papers in